Report from National Academies reaches mixed conclusions
These and other companies are taking steps to fight antimicrobial resistance
Use of rescue medications also falls in LIBERTY study
After five years, about half of recipients held onto cardiovascular benefits
Most fatalities involved children who didn’t get flu shots
Eosinophilic asthma drug is currently given based on weight
Under-users tended to be smaller, nonurban, and Western practices
Complete response letter seeks more information on CAM2038
ASP0113 missed key endpoints in phase 3 trial
32 states experience high activity levels in week ending January 13


Why the Individual Mandate Matters (and Much More) From Dr. David B. Nash

In our latest interview, the Dean of the Jefferson College of Population Health tackles a virtual alphabet soup of current events: the GOP versus the ACA, CVS buying Aetna, the role of PBMs, health care’s slice of the GDP, and the hope (and hype) of CAR T.

December 2017 interview

P&T January 2018
Table of Contents


Will Medication Price Hikes Cool Down as a Result?
Is industry consolidation a response to President Donald Trump’s repeated denunciation of high drug prices and congressional hearings on the issue? The author considers whether any of this corporate collaboration will get at some of the significant, underlying problems in the drug-pricing space.
Health Care & Law
Despite the president’s urging, congressional efforts to repeal the Patient Protection and Affordable Care Act (PPACA) have been repeatedly unsuccessful. The authors explore key actions taken by the administration and department heads that have resulted in delayed enforcement of the PPACA and relaxation of the law.
With No Cure in Sight, Experts Urge Early Diagnosis and Prompt Treatment With Better Adherence
Although a significant increase in life expectancy for people with human immunodeficiency virus was reported last spring, experts in the U.S. caution that the results are not a cause for complacency. Efforts to develop a vaccine and a cure remain essential, as do efforts to develop interventions that may improve adherence.
Meeting Highlights
We review key sessions from the 2017 AHA Scientific Sessions that included pharmacological aspects of treatment for peripheral artery disease, type-2 diabetes, percutaneous coronary intervention, atrial fibrillation, and hypertension.
The Impact of a Clinical Pharmacist
The authors present a case report illustrating how the role of a clinical pharmacist helped avert adverse consequences and promoted considerable cost-savings. This case also shows that levocarnitine may be an effective treatment for certain cases of hyperammonia-induced encephalopathy with unknown etiology.


Medication Errors
Inpatients with Parkinson’s disease require precise medication management
Prescription: Washington
CMS finalizes drastic 340B reimbursement cut for 2018
Approvals, new indications, regulatory activities, and more
Latanoprostene bunod ophthalmic solution (Vyzulta) for the reduction of intraocular pressure; letermovir (Prevymis) for prophylaxis of cytomegalovirus infection and disease after stem cell transplant; benralizumab (Fasenra) for the add-on maintenance treatment of severe asthma of an eosinophilic phenotype
Drug Forecast
Edaravone (Radicava): a novel neuroprotective agent for the treatment of amyotrophic lateral sclerosis